TY - JOUR
T1 - Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis
T2 - a histopathological study
AU - Vissing, Mille
AU - Sinius Pouplier, Sandra
AU - Munch Larsen, Lars
AU - Krog Frandsen, Stine
AU - Lodin, Alexey
AU - Lænkholm, Anne-Vibeke
AU - Gehl, Julie
PY - 2024/5/28
Y1 - 2024/5/28
N2 - BACKGROUND AND PURPOSE: Calcium electroporation (CaEP) involves injecting calcium into tumour tissues and using electrical pulses to create membrane pores that induce cell death. This study assesses resultant immune responses and histopathological changes in patients with cutaneous metastases.PATIENTS/MATERIALS AND METHODS: The aimed cohort comprised 24 patients with metastases exceeding 5 mm. Tumours were treated once with CaEP (day 0) or twice (day 28). Biopsies were performed on days 0 and 2, with additional samples on days 7, 28, 30, 35, 60, and 90 if multiple tumours were treated. The primary endpoint was the change in tumour-infiltrating lymphocytes (TILs) two days post-treatment, with secondary endpoints evaluating local and systemic immune responses via histopathological analysis of immune markers, necrosis, and inflammation.RESULTS: Seventeen patients, with metastases primarily from breast cancer (14 patients), but also lung cancer (1), melanoma (1), and urothelial cancer (1), completed the study. Of the 49 lesions treated, no significant changes in TIL count or PD-L1 expression were observed. However, there was substantial necrosis and a decrease in FOXP3-expression (p = 0.0025) noted, with a slight increase in CD4+ cells but no changes in CD3, CD8, or CD20 expressions. Notably, four patients showed reduced tumour invasiveness, including one case of an abscopal response.INTERPRETATION: This exploratory study indicates that CaEP can be an effective anti-tumour therapy potentially enhancing immunity. Significant necrosis and decreased regulatory lymphocytes were observed, although TIL count remained unchanged. Several patients exhibited clinical signs of immune response following treatment.
AB - BACKGROUND AND PURPOSE: Calcium electroporation (CaEP) involves injecting calcium into tumour tissues and using electrical pulses to create membrane pores that induce cell death. This study assesses resultant immune responses and histopathological changes in patients with cutaneous metastases.PATIENTS/MATERIALS AND METHODS: The aimed cohort comprised 24 patients with metastases exceeding 5 mm. Tumours were treated once with CaEP (day 0) or twice (day 28). Biopsies were performed on days 0 and 2, with additional samples on days 7, 28, 30, 35, 60, and 90 if multiple tumours were treated. The primary endpoint was the change in tumour-infiltrating lymphocytes (TILs) two days post-treatment, with secondary endpoints evaluating local and systemic immune responses via histopathological analysis of immune markers, necrosis, and inflammation.RESULTS: Seventeen patients, with metastases primarily from breast cancer (14 patients), but also lung cancer (1), melanoma (1), and urothelial cancer (1), completed the study. Of the 49 lesions treated, no significant changes in TIL count or PD-L1 expression were observed. However, there was substantial necrosis and a decrease in FOXP3-expression (p = 0.0025) noted, with a slight increase in CD4+ cells but no changes in CD3, CD8, or CD20 expressions. Notably, four patients showed reduced tumour invasiveness, including one case of an abscopal response.INTERPRETATION: This exploratory study indicates that CaEP can be an effective anti-tumour therapy potentially enhancing immunity. Significant necrosis and decreased regulatory lymphocytes were observed, although TIL count remained unchanged. Several patients exhibited clinical signs of immune response following treatment.
KW - Humans
KW - Skin Neoplasms/immunology
KW - Female
KW - Lymphocytes, Tumor-Infiltrating/immunology
KW - Male
KW - Aged
KW - Middle Aged
KW - Tumor Microenvironment/immunology
KW - Calcium/metabolism
KW - Aged, 80 and over
KW - Electroporation/methods
KW - Adult
KW - Necrosis/immunology
KW - Melanoma/immunology
KW - Breast Neoplasms/pathology
KW - Electrochemotherapy/methods
U2 - 10.2340/1651-226X.2024.19462
DO - 10.2340/1651-226X.2024.19462
M3 - Article
C2 - 38804839
SN - 0284-186X
VL - 63
SP - 398
EP - 410
JO - Acta Oncologica
JF - Acta Oncologica
ER -